Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698483 | 1.00 | PTGS1 (0.73) | PTGS1PTGS2KMT2AMAPK14NR3C2 | |
| SCHEMBL6509069 | 0.85 | PTGS1 (1.00) | PTGS1PTGS2KMT2ANR3C2 | |
| SCHEMBL1557809 | 0.84 | PTGS2 (0.62) | PTGS1PTGS2KMT2A | |
| SCHEMBL12404397 | 0.84 | PTGS1 (0.69) | PTGS1PTGS2KMT2A | |
| SCHEMBL14516360 | 0.77 | PTGS1 (1.00) | PTGS1PTGS2KMT2A | |
| SCHEMBL22246091 | 0.77 | PTGS1 (0.63) | PTGS1PTGS2KMT2ANR3C2 | |
| SCHEMBL3248190 | 0.77 | PTGS1 (1.00) | PTGS1PTGS2KMT2A | |
| SCHEMBL3873376 | 0.77 | PTGS2 (1.00) | PTGS1PTGS2 | |
| SCHEMBL27470184 | 0.76 | PTGS1 (0.66) | PTGS1PTGS2KMT2ANR3C2 | |
| SCHEMBL22246047 | 0.75 | KMT2A (0.49) | PTGS1PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867211-B2 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | MERCKLE GMBH (DE) | 2005-03-15 | — | — | US | disclosed |
| EP-1252163-B1 | 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY | MERCKLE GMBH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030153558-A1 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | MERCKLE GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1252163-A2 | 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY | MERCKLE GMBH (DE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057042-A2 | 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY | MERCKLE GMBH (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153558-A1 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | IL4, IL2, IL5 | PTGS1 51/4885PTGS2 70/4885KMT2A 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.